Back
Corcept Therapeutics 10K Form
Buy
87
CORT
Corcept Therapeutics
Last Price:
59.57
Seasonality Move:
3.97%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-01 | 10Q | CORT/Corcept Therapeutics Quarterly |
2023-11-01 | 10Q | CORT/Corcept Therapeutics Quarterly |
2023-08-02 | 10Q | CORT/Corcept Therapeutics Quarterly |
2023-05-03 | 10Q | CORT/Corcept Therapeutics Quarterly |
2022-11-03 | 10Q | CORT/Corcept Therapeutics Quarterly |
2022-08-04 | 10Q | CORT/Corcept Therapeutics Quarterly |
Receive CORT News And Ratings
See the #1 stock for the next 7 days that we like better than CORT
CORT Financial Statistics
Sales & Book Value
Annual Sales: | $482.38M |
---|---|
Cash Flow: | $72.19M |
Price / Cash Flow: | 46.57 |
Annual Sales: | $6.10 |
Price / Book: | 9.78 |
Profitability
EPS (TTM): | 1.26000 |
---|---|
Net Income (TTM): | $141.82M |
Gross Margin: | $475.89M |
Return on Equity: | 25.77% |
Return on Assets: | 21.04% |
Corcept Therapeutics Earnings Forecast
Key Corcept Therapeutics Financial Ratios
- The Gross Profit Margin over the past 19 years for CORT is 98.66%.
- The Selling, General & Administrative Expenses for CORT have been equal to 38.20% of Gross Profit Margin.
- The Research & Development expenses have been 38.22% of Revenue.
- The Interest Expense is 0.04% of Operating Income.
- The Net Earning history of CORT is 22.00% of Total Revenues.
- Per Share Earnings over the last 23 years have been positive in 12 years.
Corcept Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | CORT |
CUSIP: | 218352 |
Website: | corcept.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 3.7 |
Quick Ratio: | 3.49 |
Price-to-Earnings
Trailing P/E Ratio: | 63.4 |
---|---|
Forward P/E Ratio: | 34.06 |
CORT Technical Analysis vs Fundamental Analysis
Buy
87
Corcept Therapeutics (CORT)
is a Buy
Is Corcept Therapeutics a Buy or a Sell?
-
Corcept Therapeutics stock is rated a Buy
The current Corcept Therapeutics [CORT] share price is $59.60. The Score for CORT is 87, which is 74% above its historic median score of 50, and infers lower risk than normal.